Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
Musa Mayer -- breast cancer survivor, advocate, and author -- presents at SHARE in November 2011. To view a video about the First International Consensus on Metastatic Breast Cancer, visit www.sharecancersupport.org/mayer.
Navigating Nutrition During Cancer and COVID-19bkling
Nutrition can be puzzling enough, but when you add a cancer diagnosis and a global pandemic, it’s even harder to make sense of it all. Julie Lanford, MPH, RD, CSO, LDN, "The Cancer Dietitian" for Cancer Services, will help put the pieces together so you’re equipped to navigate nutrition during cancer and COVID-19.
Gain a deeper understanding of uterine and endometrial cancer symptoms, diagnosis, treatment options, and current research trends with Dr. Jason D. Wright, Division Chief of Gynecologic Oncology at New York-Presbyterian/Columbia University Medical Center. This webinar is a collaboration with the Foundation for Women's Cancer.
Communities of Color and Participation in Breast Cancer Researchbkling
40 percent of Americans belong to a minority racial or ethnic group, yet only 2 percent of cancer clinical trials have studied enough minorities to provide useful information to these populations. In this webinar Dr. Susan Love, from the Dr. Susan Love Research Foundation, presents on the importance of including communities of color in breast cancer research, the barriers to diversifying research, and what can be done to address them.
Report Back from ASCO on Metastatic Breast Cancerbkling
Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, shares her experiences from the American Society of Clinical Oncology's June 2017 Conference. She also updates us on the latest research from the conference as it relates to metastatic breast cancer.
Report Back from SGO: What’s the Latest in Uterine Cancer?bkling
Dr. Jeannine Villella, Chief of Gynecologic Oncology at Lenox Hill Hospital, provides a comprehensive update from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Dr. Villella breaks down what the research presented at the conference means for you and discusses new developments.
Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
Musa Mayer -- breast cancer survivor, advocate, and author -- presents at SHARE in November 2011. To view a video about the First International Consensus on Metastatic Breast Cancer, visit www.sharecancersupport.org/mayer.
Navigating Nutrition During Cancer and COVID-19bkling
Nutrition can be puzzling enough, but when you add a cancer diagnosis and a global pandemic, it’s even harder to make sense of it all. Julie Lanford, MPH, RD, CSO, LDN, "The Cancer Dietitian" for Cancer Services, will help put the pieces together so you’re equipped to navigate nutrition during cancer and COVID-19.
Gain a deeper understanding of uterine and endometrial cancer symptoms, diagnosis, treatment options, and current research trends with Dr. Jason D. Wright, Division Chief of Gynecologic Oncology at New York-Presbyterian/Columbia University Medical Center. This webinar is a collaboration with the Foundation for Women's Cancer.
Communities of Color and Participation in Breast Cancer Researchbkling
40 percent of Americans belong to a minority racial or ethnic group, yet only 2 percent of cancer clinical trials have studied enough minorities to provide useful information to these populations. In this webinar Dr. Susan Love, from the Dr. Susan Love Research Foundation, presents on the importance of including communities of color in breast cancer research, the barriers to diversifying research, and what can be done to address them.
Report Back from ASCO on Metastatic Breast Cancerbkling
Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, shares her experiences from the American Society of Clinical Oncology's June 2017 Conference. She also updates us on the latest research from the conference as it relates to metastatic breast cancer.
Report Back from SGO: What’s the Latest in Uterine Cancer?bkling
Dr. Jeannine Villella, Chief of Gynecologic Oncology at Lenox Hill Hospital, provides a comprehensive update from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Dr. Villella breaks down what the research presented at the conference means for you and discusses new developments.
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium bkling
Steffi Osterreich, PhD, and Rachel Jankowitz, MD, of University of Pittsburgh Cancer Institute, join Heather Hillier, breast advocate and co-chair of the first international ILC Symposium, in offering an overview of Invasive Lobular Carcinoma and highlights from the conference, which took place in Pittsburgh in September 2016. The program was presented in collaboration with MBCN.
All in the Family: Hereditary Risk for Gynecologic Cancerbkling
Knowing and understanding your inherited genetics is important for ovarian and uterine cancer patients. Dr. Melissa Frey, gynecologic oncologist at Weill Cornell Medicine, discusses how genetic factors affect women with ovarian and uterine cancer and influence treatment decisions, with a particular focus on BRCA1 & 2 and Lynch Syndrome.
This webinar was being put on in partnership with FORCE.
There are striking disparities in survival between black and white patients. Dr. Christine Ambrosone and Dr. Song Yao have led a team that has done extensive research to understand the causes of more aggressive cancer in black women. Results from their research may open the door to treatment intervention that could help eliminate these disparities, and the doctors will go over their research and discuss how we can work towards the elimination of racial gaps in breast cancer survival.
Dr. Maurie Markman, President of Science and Medicine at Cancer Treatment Centers of America, shares his expertise on the latest developments in immunotherapy for ovarian cancer.
Dr. Jennifer Mueller, gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center, will share research updates on uterine/endometrial cancer and other new developments in treatment and surgery.
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...bkling
Dr. Cliff Hudis on the latest information on new breast cancer treatments. Dr. Hudis is Chief of Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center.
HPV infection, cervical abnormalities, and cancer in HIV-infected women in Mu...Dr.Samsuddin Khan
Background: HIV-infected women are at a higher risk of cervical intraepithelial neoplasia (CIN) and cancer than women in the general population, partly due to a high prevalence of persistent human papillomavirus (HPV) infection. The aim of the study was to assess the burden of HPV infection, cervical abnormalities, and cervical cancer among a cohort of HIV-infected women as part of a routine screening in an urban overpopulated slum setting in Mumbai, India.
Methods: From May 2010 to October 2010, Médecins Sans Frontières and Tata Memorial Hospital Mumbai offered routine annual Pap smears and HPV DNA testing of women attending an antiretroviral therapy (ART) clinic and a 12-month follow-up. Women with abnormal test results were offered cervical biopsy and treatment, including treatment for sexually transmitted infections (STIs).
Results: Ninety-five women were screened. Median age was 38 years (IQR: 33–41); median nadir CD4-count 143 cells/µL (IQR: 79–270); and median time on ART 23 months (IQR:10–41). HPV DNA was detected in 30/94 women (32%), and 18/94 (19%) showed either low-grade or high-grade squamous intraepithelial lesions (LSIL/HSIL) on Pap smear. Overall, >50% had cervical inflammatory reactions including STIs. Of the 43 women with a cervical biopsy, eight (8.4%) had CIN-1, five (5.3%) CIN-2, and two (2.1%) carcinoma in situ. All but one had HPV DNA detected (risk ratio: 11, 95% confidence interval: 3.3–34). By October 2011, 56 women had completed the 12-month follow-up and had been rescreened. No new cases of HPV infection/LSIL/HSIL were detected.
Conclusion: The high prevalence of HPV infection, STIs, and cervical lesions among women attending an ART clinic demonstrates a need for routine screening. Simple, one-stop screening strategies are needed. The optimal screening interval, especially when resources are limited, needs to be determined.
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium bkling
Steffi Osterreich, PhD, and Rachel Jankowitz, MD, of University of Pittsburgh Cancer Institute, join Heather Hillier, breast advocate and co-chair of the first international ILC Symposium, in offering an overview of Invasive Lobular Carcinoma and highlights from the conference, which took place in Pittsburgh in September 2016. The program was presented in collaboration with MBCN.
All in the Family: Hereditary Risk for Gynecologic Cancerbkling
Knowing and understanding your inherited genetics is important for ovarian and uterine cancer patients. Dr. Melissa Frey, gynecologic oncologist at Weill Cornell Medicine, discusses how genetic factors affect women with ovarian and uterine cancer and influence treatment decisions, with a particular focus on BRCA1 & 2 and Lynch Syndrome.
This webinar was being put on in partnership with FORCE.
There are striking disparities in survival between black and white patients. Dr. Christine Ambrosone and Dr. Song Yao have led a team that has done extensive research to understand the causes of more aggressive cancer in black women. Results from their research may open the door to treatment intervention that could help eliminate these disparities, and the doctors will go over their research and discuss how we can work towards the elimination of racial gaps in breast cancer survival.
Dr. Maurie Markman, President of Science and Medicine at Cancer Treatment Centers of America, shares his expertise on the latest developments in immunotherapy for ovarian cancer.
Dr. Jennifer Mueller, gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center, will share research updates on uterine/endometrial cancer and other new developments in treatment and surgery.
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...bkling
Dr. Cliff Hudis on the latest information on new breast cancer treatments. Dr. Hudis is Chief of Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center.
HPV infection, cervical abnormalities, and cancer in HIV-infected women in Mu...Dr.Samsuddin Khan
Background: HIV-infected women are at a higher risk of cervical intraepithelial neoplasia (CIN) and cancer than women in the general population, partly due to a high prevalence of persistent human papillomavirus (HPV) infection. The aim of the study was to assess the burden of HPV infection, cervical abnormalities, and cervical cancer among a cohort of HIV-infected women as part of a routine screening in an urban overpopulated slum setting in Mumbai, India.
Methods: From May 2010 to October 2010, Médecins Sans Frontières and Tata Memorial Hospital Mumbai offered routine annual Pap smears and HPV DNA testing of women attending an antiretroviral therapy (ART) clinic and a 12-month follow-up. Women with abnormal test results were offered cervical biopsy and treatment, including treatment for sexually transmitted infections (STIs).
Results: Ninety-five women were screened. Median age was 38 years (IQR: 33–41); median nadir CD4-count 143 cells/µL (IQR: 79–270); and median time on ART 23 months (IQR:10–41). HPV DNA was detected in 30/94 women (32%), and 18/94 (19%) showed either low-grade or high-grade squamous intraepithelial lesions (LSIL/HSIL) on Pap smear. Overall, >50% had cervical inflammatory reactions including STIs. Of the 43 women with a cervical biopsy, eight (8.4%) had CIN-1, five (5.3%) CIN-2, and two (2.1%) carcinoma in situ. All but one had HPV DNA detected (risk ratio: 11, 95% confidence interval: 3.3–34). By October 2011, 56 women had completed the 12-month follow-up and had been rescreened. No new cases of HPV infection/LSIL/HSIL were detected.
Conclusion: The high prevalence of HPV infection, STIs, and cervical lesions among women attending an ART clinic demonstrates a need for routine screening. Simple, one-stop screening strategies are needed. The optimal screening interval, especially when resources are limited, needs to be determined.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
WCRF International Continuous Update Project (CUP). Presentation given by Giota Mitrou PhD MSc, Head of Research Funding and Science Activities, World Cancer Research Fund International (WCRF International).
CI4CC Moonshot Blue Ribbon Panel Report 20161010Warren Kibbe
Presentation to the Fall CI4CC meeting in Utah. CI4CC Moonshot Blue Ribbon Panel Report. Highlights of Vice President Biden's Cancer Moonshot and the NCI Blue Ribbon Panel Recommendations.
Cancer Council NSW Research Report Newsletter - November 2013Cancer Council NSW
Inside you will find:
Forgotten cancers: Bringing research funds and resources to bear on this area
Our Staff: 5 minutes with Dr Lini Nair-Shalliker
Our Insight: TA small change to the Death Registration Notice could save lives
Research Discovery: How cancer cells learn to resist the drug treatments
Join a Research Study - Make yourself available for research and help reduce the burden of cancer by completing a 5 minute questionnaire.
Keynote at NVIDIA GPU Technology Conference in D.C.Jerry Lee
Presentation at NVIDIA GPU Technology Conference in D.C. on how the Cancer Moonshot Task Force under Vice President Biden is using AI to help end cancer as we know it. Dr. Lee will discuss global efforts to empower A.I. and deep learning for oncology with larger and more accessible datasets.
Advancing Convergence and Innovation in Cancer Research: Seminar at Universit...Jerry Lee
Since 2003, the National Cancer Institute’s Center for Strategic Scientific Initiatives (CSSI) has worked to develop the resources and infrastructures investigators need to surmount roadblocks in cancer research. CSSI manages programs that promote technology development and cross-disciplinary collaboration and provide support for investigators in nascent and challenging research fields. This support includes funding opportunities, shared reagent and database resources, and assistance in the development of standards and protocols. CSSI also provides a network of partners in industry and government that can help NCI-funded researchers advance their technologies toward commercialization and translation. This presentation will highlight technologies including single-cell isolation and analysis techniques that have been supported through various CSSI mechanisms from proof-of-concept to translation into the clinic.
As part of the 4th Annual Early Age Onset CRC Summit theNational Colorectal Cancer Roundtable (NCCRT) Family History and Early Onset Task Group hosted a Special Symposium focused on the importance of Family Health History for colorectal cancer, including advanced adenomas, and its importance in preventing colorectal cancer. The Symposium included presentations on the current challenges and opportunities surrounding ascertainment and documentation of actionable family health history information in primary care.
Advancing Convergence and Innovation in Cancer ResearchJerry Lee
Describes NCI's Center for Strategic Scientific Initiatives activities (2005 - 2017) as well as data and technology activities of the 2016 White House Cancer Moonshot Task Force (2016 - 2017).
Inside you will find:
* 8 Australians a day saved from cancer: Over 61,000 Australian lives have been saved by improvements in cancer prevention, screening and greatment over the past 20 years
* CLEAR Study: What might happen next with the data we've collected
* Our achievements: The results of our cancer resarch over the past 20 years
* Annual resarch awards: New research projects that were awarded funding
* Join a Research Study - Make yourself available for research and help reduce the burden of cancer
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Advancing The Prevention And Cure Of Cancer
1. Advancing the Prevention and Cure of Cancer through Research, Strategic Leadership, and Partnerships Report to the National Cancer Advisory Board Geoffrey M. Wahl, Ph.D. President, AACR Bethesda, MD February 6, 2007
2. AACR and NCI - Shared Missions AACR To prevent and cure cancer through research, education, communications, and collaborations NCI Reduce the burden and eliminate adverse outcomes of cancer by leading an integrated effort to advance fundamental knowledge about cancer across a dynamic continuum of discovery, development, and delivery
3.
4.
5.
6.
7.
8.
9.
10. AACR - Driving the Scientific Agenda Identify and promote new and promising research opportunities, interventions, and strategies to hasten progress Foster creativity and innovation in cancer research through various mechanisms: - Scientific Think Tanks - Annual Meetings - Task Forces - Special Conferences - Scientific Committees - Educational Workshops - Scientific Working Groups - Publications & Website Engage in synergistic partnerships, both nationally and internationally
11. AACR - Driving the Scientific Agenda Identify and promote new and promising research opportunities, interventions, and strategies to hasten progress Foster creativity and innovation in cancer research through various mechanisms: - Scientific Think Tanks - Annual Meetings - Task Forces - Special Conferences - Scientific Committees - Educational Workshops - Scientific Working Groups - Publications & Website Engage in synergistic partnerships, both nationally and internationally
12.
13. AACR - Driving the Scientific Agenda Identify and promote new and promising research opportunities, interventions, and strategies to hasten progress Foster creativity and innovation in cancer research through various mechanisms: - Scientific Think Tanks - Annual Meetings - Task Forces - Special Conferences - Scientific Committees - Educational Workshops - Scientific Working Groups - Publications & Website Engage in synergistic partnerships, both nationally and internationally
14. AACR - Driving the Scientific Agenda Identify and promote new and promising research opportunities, interventions, and strategies to hasten progress Foster creativity and innovation in cancer research through various mechanisms: - Scientific Think Tanks - Annual Meetings - Task Forces - Special Conferences - Scientific Committees - Educational Workshops - Scientific Working Groups - Publications & Website Engage in synergistic partnerships, both nationally and internationally
15.
16.
17.
18.
19. Public Education - A Key Element for Prevention In Britain: 27% of all questioned, (34% of smokers, 36% of overweight, and 43% of poor, but only 14% of wealthy) feel they can do nothing to alter cancer risk. (Cancer Research UK study, 2007) In America: 36% feel that fate determines whether they will get cancer. (ACS Poll, Reported on CNN)
20.
21.
22.
23.
24.
25.
26.
27.
28. AACR - Driving the Scientific Agenda Identify and promote new and promising research opportunities, interventions, and strategies to hasten progress Foster creativity and innovation in cancer research through various mechanisms: - Scientific Think Tanks - Annual Meetings - Task Forces - Special Conferences - Scientific Committees - Educational Workshops - Scientific Working Groups - Publications & Website Engage in synergistic partnerships, both nationally and internationally
29. AACR - Driving the Scientific Agenda Identify and promote new and promising research opportunities, interventions, and strategies to hasten progress Foster creativity and innovation in cancer research through various mechanisms: - Scientific Think Tanks - Annual Meetings - Task Forces - Special Conferences - Scientific Committees - Educational Workshops - Scientific Working Groups - Publications & Website Engage in synergistic partnerships, both nationally and internationally
30. Global Cancer Burden B. W. Stewart and P. Kleihues, World Cancer Report , WHO-IARC. Lyon: IARC Press, 2003 New Cancer Cases 2000 - 10,000,000 2010 - 15,000,000 New Cancer Deaths 2000 - 6,200,000 2010 - 10,000,000
31. International Scientific Partnerships Italian Cancer Society, BACR, EACR, Fredrich Miescher Institute, FECS, EORTC, ESMO, IARC, ICA, ISREC, UICC Australian Cancer Society, MOGA National Health Research Institute of Taiwan, JCA, JSMO, CACA, KCA Brazilian Association of Philanthropic Institutions to Combat Cancer NCI of Canada NCI, NCCR, OVAC, Friends of Cancer Research, CRPF, NFCR, ASH, ASCO, EMS, ONS, Other Organizations, and Industry AORTIC
41. By Lance Armstrong Special to CNN AUSTIN, Texas (CNN) -- I'm not known for my patience. Patience is a polite quality and often appropriate, but it rarely gets things done. Impatience, however, is the hunger for results and intolerance for excuses and delays. Impatience got me over countless mountain passes, across the finish line in New York City and through four rounds of ruthless chemotherapy 10 years ago. Last week’s announcement by the American Cancer Association that the number of cancer deaths fell in the United States for the second year in a row was celebrated… Fighting the terrorist within B y Geoffrey M. Wahl N ovember 17, 2006 Fighting cancer bears a striking resemblance to our fight against terrorism. Cancer strikes just as randomly and unpredictably, and its causes suffering, death and great personal loss to family, friends and loved ones left behind. The Tennessean (Nashville, Tennessee) August 28, 2006 Monday 1ST Edition We're beating cancer, so why stall funding for research? Earlier this year, with surprisingly little media attention, we celebrated a major milestone in the fight against cancer -- for the first time in record-keeping history, the number of American lives lost to cancer declined.
